Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.42 |
| ▸ | TUBB | P07437 | 2/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955307 | 1.00 | CDC25B (0.50) | CDC25BCYP1A2CYP2A6ENPP2CASP3 | |
| SCHEMBL29469023 | 1.00 | CDC25B (0.50) | CDC25BCYP1A2CYP2A6ENPP2CASP3 | |
| SCHEMBL29043558 | 0.83 | CDC25B (0.44) | CDC25BCYP1A2CYP2A6ENPP2CASP3 | |
| SCHEMBL29955414 | 0.81 | CYP1A2 (0.52) | CYP1A2CYP2A6ENPP2CA1CA2 | |
| SCHEMBL4080967 | 0.81 | CYP1A2 (0.52) | CYP1A2CYP2A6ENPP2CA1CA2 | |
| SCHEMBL25991555 | 0.81 | GRM5 (0.37) | CDC25BCYP1A2CYP2A6ENPP2NQO1 | |
| SCHEMBL30182306 | 0.81 | GRM5 (0.37) | CDC25BCYP1A2CYP2A6ENPP2NQO1 | |
| SCHEMBL4080396 | 0.80 | L3MBTL1 (0.41) | NQO1MAPT | |
| SCHEMBL29957321 | 0.79 | NPC1 (0.37) | CDC25BCYP1A2CYP2A6ERN1MAPT | |
| SCHEMBL29951136 | 0.79 | ACP1 (0.41) | CDC25BERN1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250362134-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-114057744-B | Process for preparing KRAS G12C inhibitors imidazotriazines and pyrrolopyrimidine derivatives | 百济神州(北京)生物科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-114057743-B | Process for preparing KRAS G12C inhibitors imidazotriazines and pyrrolopyrimidine derivatives | 百济神州(北京)生物科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-116113416-B | Tetracyclic derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| CN-115626923-B | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240254129-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-1868998-B1 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | VFP THERAPIES (FR) | 2016-05-25 | — | — | EP | disclosed |
| US-7977354-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | INSA ROUEN (FR) | 2011-07-12 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
| EP-1868998-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | Insa Rouen (FR) | 2007-12-26 | — | — | EP | disclosed |
| EP-1731507-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | Institut National des Sciences Appliquees de Rouen (INSA) (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006103120-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CDC25B 438/4885CYP1A2 4727/4885CYP2A6 4480/4885 |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | NLN, SNCA, APP | CDC25B 2730/4885CYP1A2 586/4885CYP2A6 1106/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CDC25B 452/4885CYP1A2 4159/4885CYP2A6 3178/4885 |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CDC25B 438/4885CYP1A2 4727/4885CYP2A6 4480/4885 |
| US-20240254129-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, KRAS, HRAS | CDC25B 965/4885CYP1A2 4766/4885CYP2A6 4792/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CDC25B 438/4885CYP1A2 4727/4885CYP2A6 4480/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | CDC25B 136/4885CYP1A2 4094/4885CYP2A6 2913/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CDC25B 456/4885CYP1A2 4446/4885CYP2A6 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.